ArticleJournal of ophthalmic inflammation and infection2013
Efficacy of azithromycin 1.5% eye drops in childhood ocular rosacea with phlyctenular blepharokeratoconjunctivitis.
Article in Journal of ophthalmic inflammation and infection, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.
- Topical treatments for blepharokeratoconjunctivitis in children.The Cochrane database of systematic reviews · 2017Pooled it
- Comparison of postoperative cyclosporine 2.0% versus betamethasone 0.1% eye drops following trabeculectomy: A randomized clinical trial.Indian journal of ophthalmology · 2025Trial
- The Latest Advances in Rosacea Treatment: A Systematic Review.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Phlyctenular keratoconjunctivitis with viral triggers.World journal of virology · 2026Review
- Efficacy and safety of cyclosporine 1% eye drops for the treatment of pediatric blepharokeratoconjunctivitis.International journal of ophthalmology · 2026Article
- Advances in the Medical Management of Pediatric Blepharokeratoconjunctivitis.Advances in therapy · 2026Review
- Quantitative assessment of redness in Asian patients with recurrent blepharitis: the utility of cross-polarized light.Frontiers in medicine · 2025Article
- Deciphering Childhood Rosacea: A Comprehensive Review.Journal of clinical medicine · 2024Review
- Definition and Diagnostic Criteria for Pediatric Blepharokeratoconjunctivitis.JAMA ophthalmology · 2024Article
- Semifluorinated Alkanes as New Drug Carriers-An Overview of Potential Medical and Clinical Applications.Pharmaceutics · 2023Review
- Formulation Considerations for the Management of Dry Eye Disease.Pharmaceutics · 2021Review
- [Pediatric ocular rosacea effectively treated with topical 1.5% azithromycin eye drops].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2021Review
- A Review of Imaging Biomarkers of the Ocular Surface.Eye & contact lens · 2020Review
- Efficacy of azithromycin 1% and 1.5% ophthalmic solutions compared to tobramycin 0.3% eye drops: A systematic review and meta-analysis.SAGE open medicine · 2020Review
- Recent advances in the understanding and management of rosacea.F1000prime reports · 2014Review
- Acute allergic reaction caused by topical azithromycin eye drops: A report of two cases.Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological SocietyArticle
- An eye for azithromycin: review of the literature.Therapeutic advances in ophthalmologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe purpose of this study is to report the efficacy of azithromycin 1.5% eye drops in children with ocular rosacea and phlyctenular blepharokeratoconjunctivitis. This retrospective study from January 2009 to March 2010 included 16 children treated with lid hygiene plus azithromycin 1.5% eye drops (Azyter®): 3-day treatments (1 drop twice a day) every 10 days, reduced based on efficacy to one treatment every 15 days and then to one treatment per month.
resultsNineteen eyes of six boys and ten girls, aged 4 to 16 years (mean, 9.3 ± 4.0) were included. The disease was previously resistant to lid hygiene (all the patients), oral erythromycin (one patient), and intermittent topical steroids (six patients). The median duration of each phase of azithromycin treatment (i.e., three, two, and one treatments per month) was 2 months. Ocular inflammation was controlled by azithromycin alone in 15 patients. In one uncontrolled case, cyclosporine 2% eye drops was added at month 5. Bulbar conjunctival hyperemia resolved completely within 1 month in all eyes, whereas conjunctival phlyctenules and corneal inflammation took longer to improve, with a complete resolution within 3 to 10 months. Blepharitis grade decreased from 2.31 ± 0.79 to 1.50 ± 0.73. Treatment was stopped after a median of 6 months (from 4 to 10 months) without recurrence of corneoconjunctival inflammation (median follow-up without treatment, 11 months). Six cases of ocular irritation were reported, two of which led to treatment withdrawal.
conclusionAzithromycin 1.5% eye drops is an effective treatment for phlyctenular keratoconjunctivitis complicating childhood ocular rosacea.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.